1. Home
  2. WNW vs DRMA Comparison

WNW vs DRMA Comparison

Compare WNW & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meiwu Technology Company Limited

WNW

Meiwu Technology Company Limited

HOLD

Current Price

$4.64

Market Cap

4.3M

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.18

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNW
DRMA
Founded
2015
2014
Country
China
United States
Employees
N/A
9
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
5.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
WNW
DRMA
Price
$4.64
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
2.3M
46.0K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
$1.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.59
52 Week High
$13.52
$7.33

Technical Indicators

Market Signals
Indicator
WNW
DRMA
Relative Strength Index (RSI) 61.31 45.74
Support Level $1.37 $1.13
Resistance Level $5.56 $1.40
Average True Range (ATR) 0.76 0.06
MACD 0.01 -0.01
Stochastic Oscillator 58.51 27.08

Price Performance

Historical Comparison
WNW
DRMA

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: